Studio clinico NCT05132075 · Non-Small Cell Lung Cancer

Studio clinico NCT05132075 (fase III) risulta «attivo (non in reclutamento)» su ClinicalTrials.gov.

Patologia: Non-Small Cell Lung Cancer · Interventi registrati: JDQ443, docetaxel · Date registrate (fonte): 2022-06-15, 2026-09-03, 2021-11-24, 2026-09-25.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

Fonte: https://clinicaltrials.gov/study/NCT05132075